Please try another search
TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED is a Taiwan-based company principally engaged in the research and production of pharmaceutical products. The Company's products mainly are new chemical entities (NCEs) in infectious diseases, cancer and diabetes-related complications. Its products include Nemonoxacin, Burlxafor and TG-2349. The Company receives its revenue mainly from the authorization of Nemonoxacin products.
Name | Age | Since | Title |
---|---|---|---|
Kuo-Lung Huang | - | 2019 | Chairman of the Board, CEO, President & Chief Commercial Officer in Asia |
Chi-Kung Ho | - | - | Director |
Shih-Jen Hsiao | - | 2013 | Supervisor |
Chiung-Feng Ko | - | 2012 | Supervisor |
Ta-Shao Shih | - | 2015 | Supervisor |
Hong-Jen Chang | 67 | 2010 | Director |
Show-Chung Ho | 72 | 2013 | Director |
Kuo-Hsi Wang | - | 2009 | Director |
Ye-Hong Zhang | 61 | 2019 | Independent Director |
Shen-Fu Yu | 79 | 2019 | Independent Director |
Weng-Foung Huang | - | - | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review